GIP receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-14. Numbers and descriptions here follow the published literature rather than marketing material.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | 39-residue synthetic peptide |
| Average molecular mass | About 4813.5 Da | Free base form |
| Appearance | White to off-white powder | Solid after lyophilization |
| Solubility class | Freely soluble in water | Also soluble in neutral aqueous buffers |
| Typical storage | At or below -20 °C, desiccated | Protect from light and moisture |
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
== Behavior and diet == It is a secretive species and is seldom encountered by humans. It is active by day and night, though it is usually more active by day. This largely aquatic snake spends most of its time in the water. It is an excellent swimmer and is capable of remaining underwater for up to 10 minutes and diving to depths of 25 m (82 ft). It is a slow mover on land, and it tends to hide among rocks, in holes, or overhanging tree roots at the shoreline. It also makes use of any man-made structures, such as bridges and jetties, to hide. It is generally not aggressive, and if approached in water, it will swim away swiftly and on land will attempt to escape into water. If threatened on land, it will rear up and spread its narrow, yet prominent hood and it may hiss loudly, but it tends not to make any forward movements. It will only bite when provoked. It preys almost exclusively on fish. It may also prey on frogs, toads, and other amphibians.
After Harrison Stanford Martland (1883-1954), chief medical examiner in Essex County, detected the radioactive noble gas radon (a decay product of radium) in the breath of the Radium Girls, he turned to Charles Norris (1867-1935) and Alexander Oscar Gettler (1883-1968). In 1928, Gettler was able to detect a high concentration of radium in the bones of Amelia Maggia, one of the young women, even five years after her death. In 1931, a method was developed for determining radium dosage using a film dosimeter. A standard preparation is irradiated through a hardwood cube onto an X-ray film, which is then blackened. For a long time, the cube minute was an important unit of radium dosage. It was calibrated by ionometric measurements. The radiologists Hermann Georg Holthusen (1886-1971) and Anna Hamann (1894-1969) found a calibration value of 0.045 r/min in 1932/1935. The calibration film receives the y-ray dose of 0.045 r per minute through the wooden cube from the preparation of 13.33 mg. In 1933, the physicist Robley D. Evans (1907-1995) made the first measurements of radon and radium in the excretions of female workers. On this basis, the National Bureau of Standards, the predecessor to the National Institute of Standards and Technology (NIST), set the limit for radium at 0.1 microcuries (about 3.7 kilobecquerels) in 1941. A Radium Action Plan 2015-2019 aims to solve the problem of radiological contamination in Switzerland, mainly in the Jura Mountains, due to the use of radium luminous paint in the watch industry until the 1960s.
== The Kenner Prize and Awards at University of Liverpool == The George Kenner Prize and Lectureship was established in 1979 with a sum of £12,000 raised by subscription to commemorate the late Professor GW Kenner, Heath Harrison Professor of Organic Chemistry from 1957 to 1976 and Royal Society Professor from 1977 to 1978. The duty of the Lectureship recipient is to deliver lectures on subjects related to the study of Organic Chemistry at the University. The first of these lectures was held on 28 October 1980. Lord Todd introduced the speaker, George Kenner's former research collaborator and lifelong friend Har Gobind Khorana, Nobel prizewinner and Professor at the Massachusetts Institute of Technology. Other famous organic chemists awarded the honour of the George Kenner Lectureship include Gilbert Stork, Ryoji Noyori, Steven V. Ley, Albert Eschenmoser, John George Adami, Duilio Arigoni, and Jean-Marie Lehn. The George W. Kenner Award for graduate students was established at the University of Liverpool in 2006 to commemorate Kenner. The award is annually given to the first-year PhD student in the organic section of the Department of Chemistry who is the best in both academic and research performance.
== Interactions == Besides integrin, fibronectin binds to many other host and non-host molecules. For example, it has been shown to interact with proteins such fibrin, tenascin, TNF-α, BMP-1, rotavirus NSP-4, and many fibronectin-binding proteins from bacteria (like FBP-A; FBP-B on the N-terminal domain), as well as the glycosaminoglycan, heparan sulfate. pUR4 is a recombinant peptide that is known to inhibit the polymerization of fibronectin in a number of cell types including fibroblasts and endothelial cells. Fibronectin has been shown to interact with:
== Function == This gene encodes the alpha chain of type XVI collagen, a member of the FACIT collagen family (fibril-associated collagens with interrupted helices). Members of this collagen family are found in association with fibril-forming collagens such as type I and II, and serve to maintain the integrity of the extracellular matrix. High levels of type XVI collagen have been found in fibroblasts and keratinocytes, and in smooth muscle and amnion.
Sources: en.wikipedia.org
== History == Founded in 1997 to produce contractual mods for state of the art 3D game engines, Black Widow Games would release 14 games between their first mod, Soldier Of Fortune (created for Rysher Entertainment), and 2003. Notable releases included the Half Life spin-off, USS Darkstar (produced for PC Gamer), and the They Hunger series (produced for PC Gamer). They Hunger in particular generated extensive player discussion and was considered an example of good gameplay within the realm of Half-Life mods. To promote the 2003 film Underworld, Sony Pictures commissioned Black Widow Games a promotional tie-in mod titled Underworld: Bloodline. The mod was available on Sony Pictures' official website until the end of 2007 and remains the only officially licensed Half-Life mod tied to a Hollywood film. In October 2005, the company declared it was not possible anymore to produce full-fledged single player mods working on low budget promotional projects within reduced development cycles, because of the higher level of detail required for modern 3D engines. At this time, the company revealed it had been secretly developing for almost a year its first commercial game They Hunger: Lost Souls, based on the Half-Life 2 Source engine, a successor to their popular Half-Life survival horror mod, They Hunger, which Black Widow Software had created in 1999 and released as a bonus with copies of the PC Gamer magazine. It would feature a plotline revolving around a zombie outbreak in northeastern Europe in the 1960s.
== Collaboration == Tecemotide was developed – until Clinical trial phase II – by the Canadian biotech company Biomira Inc., which changed its company name to Oncothyreon Inc. in 2007. Oncothyreon is now located in Seattle, Washington, and it changed its name to SGEN after a merger and acquisition in March 2018. In 2001, Merck KGaA, of Darmstadt, Germany, entered into a collaboration and supply agreement with Biomira. In 2007, Merck KGaA acquired the exclusive worldwide marketing rights from Biomira, and Merck KGaA has since then been entirely responsible for the further clinical development of tecemotide. In 2008, Merck KGaA acquired the manufacturing rights for tecemotide from Oncothyreon. In 2011, Ono Pharmaceutical Company, of Japan, acquired a co-development and co-marketing license for tecemotide in Japan; Ono paid Merck KGaA 5 million euros.
) is typically set to a value of 1 to increase the readability of the exchangeability parameter estimates (since it allows users to express those values relative to chosen exchangeability parameter). The practice of expressing the exchangeability parameters in relative terms is not problematic because the
Two years prior, the French had refused Ho's proposal of a similar status within the French Union, albeit with some restrictions on French power and the latter's eventual withdrawal from Vietnam. However, they were willing to deal with Bảo Đại as he represented a non-radical option who could rally behind him the non-Communist nationalist movement. In January 1950, France officially recognized the nominal "independence" of the unified State of Vietnam, led by Bảo Đại, as an associated state within the French Union. However, France still controlled all foreign policy, every defense issue and would have a French Union army stationed in the country with complete freedom of movement. Within the framework of the French Union, France also granted independence to the other nations in Indochina, the Kingdoms of Laos and Cambodia. In January 1949, the Vietnamese National Army was created to go along the formation of the new Vietnamese associated state. This was meant to bolster French numbers as their army found itself outnumbered by the People's Army of Vietnam at this point in the war. To this end, the CEFEO provided some of its officers to lead these new divisions.
Nitrate reductase (NAD(P)H) (EC 1.7.1.2, assimilatory nitrate reductase, assimilatory NAD(P)H-nitrate reductase, NAD(P)H bispecific nitrate reductase, nitrate reductase (reduced nicotinamide adenine dinucleotide (phosphate)), nitrate reductase NAD(P)H, NAD(P)H-nitrate reductase, nitrate reductase [NAD(P)H2], NAD(P)H2:nitrate oxidoreductase) is an enzyme with systematic name nitrite:NAD(P)+ oxidoreductase. This enzyme catalises the following chemical reaction
Sources: en.wikipedia.org
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.
The C20 fatty diacid promotes tight binding to serum albumin. That binding reduces renal clearance and extends circulation time compared with an unmodified peptide of similar length.
It is not fully established. Studies indicate that both receptors contribute to the observed effects, but the exact split between the two signaling pathways in humans remains an open question.
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。